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Acrolein Depletes the Neuropeptides CGRP
and Substance P in Sensory Nerves in Rat
Respiratory Tract
by David R. Springall,* John A. G. Edginton,t Philip N.
Price,t Dennis W. Swanston,t Carole Noel,* Stephen R.
Bloom,* and Julia M. Polak*
The mammalian respiratory tractis denselyinnervatedbyautonomic andsensorynervesaroundair-
ways and blood vessels. Subsets of these nerves contain a number of putative neurotransmitter
peptides, such as substance Pand calcitonin gene-relatedpeptide (CGRP) in sensory nerves and vaso-
activeintestinalpolypeptide(VIP), possiblyservingautonomicfunctions. CGRPisalsofoundinendocrine
cells inratairway epithelium. These peptides are allpharmacologically potent effectors ofbronchial
andvascular smooth muscleandbronchial secretion. Theirfunctions in vivoare lesswellestablished.
We have therefore examined the effects of inhaled acrolein, a sensory irritant, on three pulmonary
neuropeptides: CGRP, substanceP,andVIEP. Groupsofrats(n = 3each)wereexposedfor 10mintoacrolein
in air (Ct = 510, 1858, and 5693 mg.min/m3) or to air alone. Fifteen minutes later they were killed
(pentabarbitone IP) andtheirrespiratorytractswere dissectedandfixedin0.4% p-benzoquinone solu-
tion. Cryostat sections were stainedby indirect immunofluorescence forageneral nerve marker (PGP
9.5)andneuropeptides. Theacrolein-treated animalshadadose-related decrease intrachealsubstance
P- and CGRP-immunoreactive nerve fibers compared with controls. No change was seen intotal nerve
flberdistributionandnumber(PGP9.5) orVIPimmunoreactivity, norinCGRP-immunoreactiveepithelial
endocrine cells. It is concluded that the rat tracheal peptidergic nerves are asensitive indicator ofin-
haled irritant substances. Their reduced immunoreactivity may be because of a release of sensory
neuropeptides that could play a role in the physiological response to irritant or toxic compounds.
Introduction
The respiratory tract is densely innervated by
sensory and automatic fibers (1) that together with
endocrine cellsintheepithelium ofairwaysformthe so-
called diffuse neuroendocrine system. Subsets of both
the nerves and endocrine cells are known to contain
bioactive regulatory peptides that can act locally as
hormones orpossibly asneurotransmitters/modulators
(2). Theneuropeptidesincludesubstance P(3)andother
tachykinins(4); calcitoningene-relatedpeptide(CGRP),
also found in endocrine cells (5); vasoactive intestinal
polypeptide (VIP) (6); peptide histidine isoleucine or
methionine (PHI/M) (7); galanin (8); and neuropeptide
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tyrosine(NPY)(9,10). Thesepeptideshavestrongactions
on vascular and airway smooth muscle and glandular
secretion (11,12). The distribution ofnerves containing
the different peptides may be analyzed by examining
tissuesectionsimmunostained withspecific antiserato
each peptide (2).
Oftheneuropeptides intherespiratorytract, twoare
known to be predominantly in the sensory nervous
system. These are CGRP and substance P. This sensory
system is known to respond to inhaled irritants such as
cigarette smoke (13), resulting in a release of neuro-
peptidesandthusdecreasingthepeptideimmunoreac-
tivity of the fibers. Such local release of substance P
following nerve stimulation has been observed (12,14)
and shown to cause local vasodilatation and plasma
extravazation (13).
Acrolein is an unsaturated aliphatic aldehyde with
toxic and sensory irritating effects (15-19). It is a com-
ponentofcigarettesmoke(20), engineexhausts(21), and
industrialby-products(22). Wehave,therefore, examined
byimmunocytochemicaltechniquesthe effectofacute
exposure to acrolein vapor in the rat. The aim was toSPRINGALL ETAL.
Table 1. Characteristics of antisera used in this study.
Antigen Tyrpe Carriera Cross-linker Dilution Absorptionb
PGP 9.5 Whole molecule, human brain - 1:1500 0.1
Rat aCGRP Whole molecule, synthetic BSA Glutaraldehyde 1:200 0.5
Substance P Whole molecule, synthetic BSA Glutaraldehyde 1:1000 1.0
VIP Whole molecule, synthetic KLH Glutaraldehyde 1:2000 1.0
aBSA, bovine serum albumin; KLH, keyhole limpet hemocyanin.
bConcentration of homologous antigen (nmole/mL diluted antiserum) required to abolish immunostaining in tissues used in this study.
All peptide antisera were raised in rabbits at the Royal Postgraduate Medical School, Hammersmith Hospital, London, UK. Antiserum
to PGP 9.5 was purchased from Ultraclone, Cambridge, UK.
determine whether ornotacroleincould causechanges
inthe innervation ofthe respiratory tract, includingthe
neuropeptides, and thus whether such an examination
would prove tobe ausefulandsensitive indicatorofthe
acute response to such irritants.
Materials and Methods
Groups of three Porton strain Wistar female rats
(weight 190-210g) wereexposedfor 10mininindividual
wiremesh cagesin a501 (aluminum andglass)chamber,
through which air was drawn at 120 L/min. Acrolein
vaporconcentrations weregenerated inthechamberby
injecting liquid acrolein (BDH) at a constant rate from
a syringe drive into the chamber inlet, through a
27-gauge needle surrounded by a concentric air jet.
Vapor concentrations were set by adjusting the syringe
drive delivery rate. Three concentrations of acrolein
were used withdifferent groupsofanimals, andanother
group (controls) was exposed to air alone.
Acrolein chamberconcentrations weredeterminedby
sampling at 1 L/min into distilled water in a glass bub-
bler, cooled in an ice bath; the sample was diluted to a
suitablevolume(25, 50, or 100 mL), andtheabsorbance
wasmeasuredin aUVspectrophotometerat209 nm. The
acrolein concentration was calculated by comparison
with a standard curve.
Fifteen minutes after termination of exposure the
animals werekilledbypentobarbitone overdose injected
IP. The thorax was opened, the respiratory tract
dissected out, andspecimens weretakenfrom upperand
lower trachea and lung (a 3-mm thick slice at the hilar
level ofright lowerand left lobes). The tissues were im-
mediately fixed by immersion for 2 hr in 0.4% solution
ofp-benzoquinone in phosphate-buffered saline (PBS)
(0.01 mole/L phosphate buffer, pH 7.4, containing 0.15
mole/LNaCl), thenwashedandstored at40CinPBS con-
taining 0.15 mole/L sucrose and 0.01% sodium azide.
Cryostat blocks were prepared and frozen sections (7
,umthick)taken up onpoly-L-lysine-coated slides. From
eachblock, onesection wasstainedbyhematoxylinand
eosin for morphological examination, and 10 sections
wereimmunostained foreachantiserum. Antiseratothe
generalneuronalmarkerPGP9.5(23)andthe neuropep-
tides CGRP, substance P, and VIP were used with a
modified indirect immunofluorescence method (5).
Briefly, slides were placed for30 min in PBS containing
0.2% (v/v) Triton X-100, and the sections were then in-
cubated for 16 hr at 4°C with appropriately diluted
primaryantiserum(Thble 1). Slides werewashedinthree
bathsofPBSfor 10mineachandtheprimaryantiserum
wasreappliedfor4hrat roomtemperature. Slides were
washed again (3 x 5 min) in PBS, goat anti-rabbit IgG
antibodyconjugatedtofluoresceinisothiocyanate(Miles
Laboratories), diluted 1:200, appliedfor60min, rewash-
ed asbefore inPBS. Slides weremountedinPBSglycerol
(1:9 v/v) and viewed using an Olympus Vanox
fluorescence microscope. Photographs were taken on
KodakTri-XfilmdevelopedinAcutol. Thespecificity of
immunostaining wasverifiedbyrepeatingtheimmunos-
taining but by using primary antiserum absorbed with
homologous antigen (Thble 1), which abolished the
immunoreactivity.
The number of immunoreactive nerve fibers was
assessed visuallyinall sectionsand graded from absent
(-)toabundant(+ + + +). Thescreening wasperformed
randomlywithoutknowledgeofthetreatmentgroupby
one observer, and 1 in 10 ofthe slides were checked by
another observer to ensure consistency.
Results
Acroleinchamber concentrations and Ct values are
given in lhble 2. The low- and medium-dose animals
showed no major changes in respiratory tract mor-
phology in comparison with controls. In the medium-
dose groupthere wasslightedemaand occasionalsmall
areas ofbleeding into the lungs; this was more marked
in the high-dose-treated animals, in which many ofthe
airways contained cellular serous exudate. The results
of immunostaining are summarized by the diagrams in
Figures 1-3.
PGP 9.5
The overallinnervationofallthree areasofrespiratory
tract examined showed no change with acrolein treat-
ment. Immunoreactive nerve fibers were seen in the
lTble 2. Concentrations and doses of acrolein used.
Concentration, Cta
Animal group mg/m Parts per million mg/min/m
Controls 0 - -
Low dose 51 22.2 510
Medium dose 185.8 81.1 1858
High dose 569.3 248.6 5693
aCt, concentration x time.
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FIGURE 1. Numberof nerve fibers immunoreactive forPGP 9.5 and
neuropeptides in uppertracheaofacrolein-treated and control rats.
The histogram bars represent the modal value in 10 sections from
three animals foreach dose group, the T-bars represent the range
of values. The number of immunoreactive nerves is a visual esti-
mate: 0, no nerves seen; + sparse; + +, few; + + +, moderate;
+ + + +, abundant.
Nerves in lower trachea
?i *+ CGRP
D Substance P
control lowdose moddos hbghdose
Fi(;JJRF, 2. Numbersofnerve fibers immunoreactive forPGP9.5 and
neuropeptides in lower trachea, as shown in Figure 1.
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FIGURE 3. Numbersof nerve fibersimmunoreactive forPGP9.5 and
neuropeptides in lung, as in Figure 1.
FIGURE 4. Tracheal section immunostained with antiserum to the
general neural antigen PGP 9.5. Immunoreactive nerve fibers
(arrows) are seen within and below the epithelium (E) of (a)
control and (b) high-dose acrolein-treated rats. L, lumen. (a)
x600, (b) x320.
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2: 01)
a
0
0
E
z
153SPRINGALL ETAL.
epithelium, mucosa, smooth muscle and blood vessels
of the trachea (Fig. 4), and around airways and blood
vesselsinthelung(Fig. 5). Scatteredfiberswerealsoseen
in the lung parenchyma and endocrine cells in the air-
way epithelium.
CGRP and Substance P
These two neuropeptides are considered together
becausetheyhadsimilardistributionsand responses to
acrolein. Immunoreactive fibers(Figs. 6-8)wereseenin
andbelowairwayepithelium, insmoothmusclebundles
andsurroundingbloodvessels, andinaproportionofthe
fibers in nerve bundles in the tracheal adventitia. The
numberofCGRP-immunoreactivefiberswassomewhat
greater than those that have substance P staining. The
acrolein-treated animals showed a progressive dose-
dependent decrease in the number ofnerves immuno-
reactiveforeitherpeptidebutmostmarkedlysubstance
P (Figs. 1-3, 6-8), and the effect spread further down
therespiratorytractwithincreasingdoses. Thus, thelow
dose (Ct = 510 mg.min/m3) caused little change in
CGRP-immunoreactive nerves with a noticeable
decreaseinthoseimmunoreactive forsubstance Pinthe
trachea(Fig. 7), particularly the fibersneartheepithel-
ium. The moderate dose (Ct = 1858 mg.min/m3) caus-
edagreaterdepletionofCGRPandsubstance Pimmuno-
reactivityandonlyafewfiberswerestainableinthehigh
dose (Ct = 5693 mg.min/m3)group (Fig. 7). Inthe lung,
changes were seen only in animals receiving the high
dose ofacrolein, and the depletion was more markedly
seen in the substance P-immunoreactive fibers (Figs. 6
and 8). No obvious changes were detected in numbers
ofepithelial endocrine cells immunoreactive forCGRP.
VIP
Immunoreactive nerve fiberswereseenprincipally in
vascular and airway smooth muscle and around glands
in the trachea. No change wasseen in their numbers in
the acrolein-treated animals compared with controls
(data not shown).
Discussion
This study has shown that acute treatment with
acrolein results in a decrease in the number of nerves
immunoreactive forregulatory peptides. Also, it shows
that this response is dose related.
Acrolein is a sensory irritant compound, and it is
therefore relevant that the two peptides showing
changes are substance P and CGRP; these are the two
mainneuropeptidesinthesensoryinnervationofrodent
respiratorytract(24,25). Thissuggeststhattheacuteex-
posure to acrolein affects only the sensory nerves and
not the autonomic fibers, at least not those containing
VIP(mainlypostganglionicparasympathetic). Italsocon-
firms that acrolein is a sensory irritant. No obvious
changesinCGRP-immunoreactive endocrinecellswere
seen, butafullquantitative study wasnot undertaken.
FIGURE 5. PGP 9.5 immunoreactive nerve fibers surrounding bron-
chioles (L, lumen) in the lung of (a) and control (b) high-dose
acrolein-treated rats. No change in the number of nerves is seen
in the treated animals. x160.
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FIGURE 6. CGRP-immunoreactive nerve fibersaround abronchus(L,
lumen)inlungof(a)high-doseacrolein-treated and(b)control rats.
Thereisonly aslightdecreasein nervefibersstained in thetreated
group; compare with substance P in lung (Fig. 8). x320.
FIGURE 7. Substance P-immunoreactive nervefibers in rat trachea.
Thenumberofnerves(arrows)inepithelium(E)decreasefromthe
controlanimals(a), tothelowdoseacroleintreatment(b), and are
almost absent from the high-dose treated animals (c). The diffuse
stainingbelow the epithelium in(c) is due to autofluorescence of
collagen fibers. x320.
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FIGURE 8. Substance P-immunoreactive fibers (arrows) around
bronchioles (L)lumen, (E)epithelium inlung, showing areduction
in numbers in high dose acrolein-treated rats (b) compared with
controls (a). Note that the diffuse staining below the epithelium
in (a) and (b) is due to autofluorescence of collagen fibers. x320.
Itis, therefore, possiblethatalthoughthesecellsmaybe
sensory (5), they do not respond to acrolein.
Because ofthebrieftimebetweeninitial exposure to
acrolein and fixation oftissues, it is unlikely that there
wasanymajorstructuraldamagetothenerves,although
acrolein is known to cause morphological changes in
nerves in the olfactory epithelium of chronically
exposed animals, even at low doses (26). The lack of
damageisalsosuggestedbytheunchangedimmunoreac-
tivity for PGP 9.5, a general neural antigen (23) that
rapidly disappears following a nerve lesion. Therefore,
the reduced CGRP and substance P immunoreactivity
mustbeduetorelease ofthepeptidesfromthe sensory
nerve fibers by antidromic stimulation. That this
mechanism canoccurhasbeenshownbystudiesdetec-
ting the released peptides following nerve stimulation
(14). This has been shown to occur with other sensory
irritants such as cigarette smoke both for substance P
(13) and for CGRP, both by immunocytochemistry and
radioimmunoassay (unpublished observation).
The apparent greater sensitivity of substance
P-immunoreactivenervesisinteresting, SubstancePand
CGRP are known to be co-localized in some sensory
nerves(12,27), butintherattherearemoreCGRP-than
substanceP-immunoreactive nervecellbodiesinganglia
innervating the respiratory tract (25). Thus, it is possi-
blethatsomesensorynervescontainCGRPalone. Where
there is co-localization, the peptides are both found in
the same secretory granule (27) and therefore must be
co-released, which permits CGRP to potentiate the ac-
tions of substance P (28). It is possible, therefore, that
this type of nerve is more sensitive to acrolein and
releasesitsstoredpeptidesatlowerlevelsofstimulation
than those containing CGRP alone, resulting in an ap-
parentlygreaterdecreaseofimmunoreactivesubstance
P nerves than CGRP nerves. Whateveris the case, sub-
stance P appears to be a more sensitive indicator of
neural response to sensory irritants than is CGRP.
This conclusion is amplified by the observation of a
decrease in substance P immunoreactivity in the lung
at the high dose level of acrolein, whereas CGRP was
littleaffected. Theeffectsofsensoryirritationwereless
marked inthe lungthan thetrachea, probablybecause
ofthehighaqueoussolubilityofacroleinresultinginab-
sorption of most of the vapor in the upper respiratory
tract (29). It is therefore probable that had the nasal
mucosabeenstudiedhere, decreasesinsensorypeptides
would have beendetected atloweracrolein concentra-
tions than in the trachea.
The concentrations ofacrolein used in this study are
high(22, 81, and249ppm), comparedwiththeRD50con-
centration of 1.7 ppm (26). It would be interesting to
determine whetherthe use oflowerconcentrationsfor
alongertimetogiveequivalentdoseswouldhavesimilar
effects onpeptidergicnerves. Inratsexposedtocigarette
smoke, the effectsonneuropeptidesofasingleexposure
are reduced if the animals have been acclimatized to
smoke (unpublished observations).
Inconclusion, thisstudyhasdemonstratedthatacute
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acroleinexposure causesamarked, dose-related deple-
tionofsensoryneuropeptidesintheratlowerrespiratory
tract. Evidence suggests that this is due to release of
CGRP and substance P from nerve terminals; these
released peptides could be involved in the response to
acroleinbycausingvasodilatationandbronchoconstric-
tion. Thus, it is proposed that investigation of changes
in sensory neuropeptides in trachea may be a sensitive
indicator of the response to sensory irritants.
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